Eiger Biopharmaceuticals (NASDAQ:EIGR) posted its quarterly earnings results on Friday. The biotechnology company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.12, Bloomberg Earnings reports.
Shares of NASDAQ:EIGR traded up $0.75 during midday trading on Friday, reaching $10.00. 53,138 shares of the company’s stock were exchanged, compared to its average volume of 89,320. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $103.82 million, a price-to-earnings ratio of -2.06 and a beta of 1.60. Eiger Biopharmaceuticals has a fifty-two week low of $9.30 and a fifty-two week high of $10.00.
In related news, insider Joanne Quan sold 4,000 shares of the firm’s stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $10.00, for a total transaction of $40,000.00. Following the completion of the sale, the insider now directly owns 4,000 shares of the company’s stock, valued at approximately $40,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.90% of the stock is currently owned by company insiders.
Several research firms have recently commented on EIGR. Oppenheimer set a $26.00 price target on Eiger Biopharmaceuticals and gave the stock a “buy” rating in a report on Friday. ValuEngine upgraded Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, April 13th. B. Riley began coverage on Eiger Biopharmaceuticals in a report on Wednesday. They set a “buy” rating and a $24.00 price target on the stock. Wedbush reiterated an “outperform” rating and set a $36.00 price target on shares of Eiger Biopharmaceuticals in a report on Thursday, April 26th. Finally, Zacks Investment Research lowered Eiger Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, March 15th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $27.11.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.